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Incidence rate
Adverse reaction No. (lOO' patient-years)
Bone marrow 6 6.6
Renal stones 5 5.5








importance of this observation is that the adverse drug
reaction (ADR) profile may be different in South Africa,
perhaps due to a more severe disease profile.
ADRs were graded from 1 (mild) through 4 (severe)
according to a World Health Organisation [WHO)
classification. ADRs were experienced by 190 children,
representing 39.3% of the total. There were 289 reactions,
of which 42 were grade 3 or 4 (14.5%). The grade 3 and 4
ADRs are shown in Table I. Two persistently reported
adverse reactions were diarrhoea and raised creatinine.
There was only 1 death attributed to the ARV
medication.
Fig. 2. Number and percentage of four most common adverse
drug reactions in the Italian Collaborative Multicentric Study
(BM ~ bone marrOw toxicity).
TABLE I. GRADE 3 AND 4 ADVERSE EVENTS SEEN IN HIV-
PDsmVE CHILDREN IN THE ITAUAN COUABORATlVE
MUlTICENTRIC STUDY
The four most common ADRs are shown in Rg. 2. They were
lipid abnormalities (20%), bone marrow toxicity, liver
function abnormalities (elevated aspartate aminotrans-
ferase/alanine aminotransferase (AST/ALn and skin rashes
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There are two ways in which children may be exposed to
ARVs. One is in utero or postnatal exposure as a result of
vertical transmission prophylaxis (VrP), and the other is
treatment for symptomatic HIV infection.
Fig. 7. Disease profile ofHN-positivechildren in the Italian
Collaborative Multicentric Study.
Antiretroviral (ARV) toxicity is an important issue that must
be fully appreciated by prescribing doctors. While the
benefits of therapy are well documented, toxicity is of
concern and may be extremely serious, occasionally
resulting in fatality. However, most side-effects are not
serious and are reversible.
SYMPTOMATIC INFECTION
Castelli-Gattinara etal.' presented a comprehensive review
of ARV toxicity at the XIV International AIDS Congress in
Barcelona in July 2002. As this is, to my knowledge, the
largest review of ART toxicity in children, it is worth close
attention. The Italian Multicentric Collaborative Study' was
conducted between 1998 and 2000 and included 29
institutions.
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ANTIRETROVIRAl TOXICITY IN CHILDREN
Four hundred and eighty-four patients were enrolled in the
study (male/female ratio 0.9). The median age was 6.4 years
(range 1 month - 18 years). The median follow-up was 709
days, but again there was a wide range (8 - 1 381 days).
The clinical and immunological profile (Rg. 1) suggested
less severe disease than is commonly seen in South Africa.
In the Italian group 71% of patients were either
asymptomatic (N) or mildly symptomatic (A). In contrast,
68% of children first presenting at the Tygerberg Family
Clinic are either stage B (moderate) or C (severe). The
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1< 1(010). Less frequent side-effects were renal stones,
lipodystrophy and gastrointestinal disturbances, including
nausea and vomiting INNl.
Lipodystrophy and lipid abnormalities were more common
in children over 10 years of age, and there was a marginally
higher incidence in females. This observation is of
importance as these abnormalities, currently rare in
children in South Africa, will become more important with
longer use of ARVs.
Another important observation was that the relative risk of
ADRs increased quite significantly when more than three











P < 0.05 for all.
Fig. 3. Increased relative risk of toxicity when mare than three
antiretraviral drugs are used simultaneously (GI ~
gastraintestinal; CNS ~ central nervous system).
Many ADRs can be linked to specific ARVs. Examples are
listed in Table 11.
The Southern African HIV Clinicians Society's Paediatric
Discussion Group, led by Paediatric Sub-committee
Chairman, Dr Leon Levin, was recently informed by Or
TABLE 11. SIDE-EFFECTS UNKED TO SPECIFIC
ANTIRETROVIRAL AGENTS
Dru9 Class Side-effect
Ritonavir [RlV) PI Unpleasant taste may lead to
drug failure




Stavudine [d4D NRTI Peripheral neuritis
All Pis Hyperlipidaemia
Abacavir [ABC) NRTI Fatal hypersensitivity
reactions: gastrointestinal and
respiratory symptoms, skin
eruptions, fever and elevated
liver enzymes (AST or ALD
Nevirapine [NVP) NNRTI Skin rash and hepatotoxicity
PI ~ protease inhibitor: NR1l- nucl~der~ transcriprasc inhibitor; NNRTl _ non-
nudeosidtr~ tJanscriptase inrobitor.
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Tammy Meyers that a toddler being treated with
didanosine (ddl) + stavudine (d4n + nevirapine (NVP) had
died of lactic acidosis and hepatic steatosis.
VERTICAL TRANSMISSION - THE
ANTIRETROVIRAL-EXPOSED INFANT
In the antiretroviral-exposed infant mitochondrial toxicity
may occur more frequently than in older children. ARVs
have an affinity for mitochondrial gamma-polymerase
which depletes mitochondrial deoxyribonucleic acid IONA)
and causes dysfunction. Mitochondrial dysfunction is
generally associated with long-term use of NRTls and
usually resolves when the drugs are discontinued.
In 1999 Blanche et al.' reported on 8 patients with
mitochondrial dysfunction following perinatal exposure to
the nucleoside analogues. Four had been exposed to
zidovudine (ZOV) alone and 4 to ZOV plus lamivudine. Two
infants died. These data have not been replicated
elsewhere. For example, no excess mortality was reported in
follow-up of infants receiving ZDV after the landmark 076
study. In a large database of over 20000 infants and 223
infant deaths in several cohorts followed up in the USA, no
deaths suggestive of mitochondrial toxicity were reported.
However, the majority of infants were exposed to ZDV
alone.'
In the PETRA trial' involving 1 798 children, the majority of
whom were exposed to ZDV and lamivudine, there was no
excess mortality. However, a single case of severe transient
neonatal lactic acidosis with prophylactic ZDV was
reported in Switzerland by Scalfaro et 0/.' in 1998. It
resolved when the drug was discontinued. This report
suggests the need for continuing vigilance.
In conclusion, ARV toxicity is of concern, especially when
wider access to these drugs is becoming possible. It would
be very helpful to have a mechanism for multi-centre data
collection in order to monitor toxicity and efficacy. This
could possibly be coordinated through a national body
such as the Medical Research Council or a university-based
department of pharmacology.
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